Compare Davita Inc (DVA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Revvity Inc — how do they compare? Davita Inc trades at $179.98 (market cap $11.38B), while Revvity Inc trades at $116.09 (market cap $12.91B). The key difference: Davita Inc and Revvity Inc are close in size by market cap, and Revvity Inc pays a 0.24% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | RVTY | |
|---|---|---|
Market Cap | $11.38B | $12.91B |
Sector | Health | Technology |
52-Week High | $240.96 | $117.75 |
52-Week Low | $103.87 | $82.26 |
Enterprise Value | $24.10B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
